Related Experiment Video
Updated: Aug 8, 2026
Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery
Published on: March 27, 2018
The effects of lipid-lowering therapy on graft patency in coronary bypass surgery patients
Mutasim Sungun1, Melih Hulusi Us, Rifat Eralp Ulusoy
1Department of Cardiovascular Surgery, Gulhane Haydarpasa Military Teaching Hospital, Kadikoy, Istanbul, Turkey. mutasimsungun@yahoo.com
Insights
Lipid-lowering treatment (LLT) significantly improves graft patency in coronary artery bypass grafting (CABG) patients. This treatment reduces ischemic events and enhances long-term graft survival, supporting its use in post-CABG care.
Area of Science:
- Cardiovascular Surgery
- Pharmacology
- Medical Research
Background:
- Investigating the impact of lipid-lowering treatment (LLT) on graft patency after coronary artery bypass grafting (CABG).
- Assessing the efficacy of LLT in patients with elevated cholesterol and LDL levels post-CABG.
Purpose of the Study:
- To determine if LLT influences graft patency in CABG patients.
- To compare graft patency rates between CABG patients who received LLT and those who did not.
Main Methods:
- Retrospective study of 209 CABG patients with high cholesterol/LDL.
- Patients divided into two groups: LLT post-CABG (group 1) and no LLT (group 2).
- Follow-up angiography assessed graft patency over a median of 5.2 years.
Main Results:
- Group 1 (LLT) showed a 42% reduction in ischemic events and deaths.
- 5-year graft patency was higher in group 1 for specific grafts (e.g., 95% LIMA-LAD vs. 90%, 66% RCA-SVG vs. 30%).
- Overall higher graft patency observed in the LLT group.
Conclusions:
- LLT is associated with improved graft patency in CABG patients.
- The findings support the routine use of LLT to enhance long-term outcomes after CABG.
- LLT may reduce ischemic events and improve graft survival post-surgery.
Background:
Our aim was to investigate the effects of lipid-lowering treatment (LLT) on graft patency in coronary artery bypass grafting (CABG) patients.
Methods:
A total of 209 CABG patients (95 men, 45%) with a total cholesterol level above 200 mg/dL and a low-density lipoprotein level above 100 mg/dL were included. Patients were divided into 2 groups on the basis of administration of LLT after CABG: group 1 received LLT after the operation (those patients undergoing operations after 1998, n = 102, 49% male) and group 2 did not receive LLT after the operation (those patients undergoing operations between 1992 and 1998, n = 107, 42% male). Median duration of follow-up was 5.2 years. Follow-up angiography could be obtained in 108 (52%) patients (56 in group 1, 52 in group 2).
Results:
There was a 42% reduction in ischemic events and deaths in group 1, and 60% of these patients had a symptom-free or event-free period for 6 years. The 5-year graft patency for left internal mammary artery-to-left anterior descending artery grafts in group 1 was 95%, and the corresponding figure was 90% in group 2. Right coronary artery-to-saphenous vein graft patency was 66% for group 1 and 30% for group 2. Circumflex artery-to-saphenous vein patency rate was 59% for group 1 and 53% for group 2. A higher graft patency was found in group 1 as a whole.
Conclusion:
Results of this retrospective study support the fact that LLT provides a higher graft patency for CABG patients.
